Jazz Pharmaceuticals plc (JAZZ) recently provided an update on their Phase 3 trial of Cannabidiol Oral Solution for treatment-resistant epilepsies in Japan. The trial did not achieve its primary efficacy endpoint, which was a predefined percentage change in seizure frequency during the 16-week treatment period compared to baseline in Japanese pediatric patients. Despite this, there were numerical improvements observed in both the primary and several secondary endpoints. Importantly, no new safety concerns emerged during the trial.
This Phase 3 open-label, single-arm clinical study assessed the safety and efficacy of Cannabidiol Oral Solution (marketed globally as Epidiolex/Epidyolex) in managing seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), and Tuberous Sclerosis Complex (TSC) in Japanese pediatric patients.
"We continue to gather data on Japanese patients and intend to collaborate with regulatory authorities in Japan regarding a potential New Drug Application (JNDA). We recognize the substantial unmet needs of patients in Japan living with rare epilepsies and extend our gratitude to the investigators, patients, and caregivers involved in this trial," stated Rob Iannone, Executive Vice President and Global Head of Research and Development at Jazz Pharmaceuticals.
